Acute rejection, T-cell-depleting antibodies, and cancer after transplantation

Transplantation

Volumn 97, Issue 8, 2014, Pages 817-825

  Lim, Wai H ^a   Turner, Robin M ^b   Chapman, Jeremy R ^c   Ma, Maggie K M ^d   Webster, Angela C ^b,c,e   Craig, Jonathan C ^b,e   Wong, Germaine ^b,c,e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d QUEEN MARY HOSPITAL   (Hong Kong)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

ANZDATA; Cancer; Epidemiology; Kidney Transplantation; Rejection; T cellYdepleting antibody

Indexed keywords

T CELL DEPLETING ANTIBODY; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HEART DEATH; HUMAN; KIDNEY TRANSPLANTATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEOPLASM; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; T CELL DEPLETION; THYROID CANCER; UROGENITAL TRACT CANCER;

ACUTE DISEASE; ADULT; AUSTRALIA; AUTOANTIBODIES; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG NEOPLASMS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELANOMA; MIDDLE AGED; NEW ZEALAND; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; T-LYMPHOCYTES; UROGENITAL NEOPLASMS;

EID: 84899477309     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442773.38510.32     Document Type: Article

References (37)

1. Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groupsand quantifying absolute risk of cancer after kidney transplantation: acohort study of 15,183 recipients. Am J Transplant 2007; 7: 2140.
2. Vajdic CM, van Leeuwen MT, McDonald SP, et al. Increased incidenceof squamous cell carcinoma of eye after kidney transplantation. J NatlCancer Institute 2007; 99: 1340.
3. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excesscancer in dialysis and transplantation. Nephrol Dialysis Transplant2009; 24: 3225.
4. Birkeland S, Lokkegaard H, Storm H. Cancer risk in patients on dialysisand after renal transplantation. Lancet 2000; 355: 1886.
5. Vajdic C, McDonald S, McCredie M, et al. Cancer incidence beforeand after kidney transplantation. JAMA 2006; 296: 2823.
6. Grulich A, van Leeuwen M, Falster M, et al. Incidence of cancers inpeople with HIV/AIDS compared with immunosuppressed transplantrecipients: a meta-analysis. Lancet 2007; 370: 59.
7. Wong G, Turner RM, Chapman JR, et al. Time on Dialysis and CancerRisk After Kidney Transplantation. Transplantation 2013; 95: 114.
8. Webster A, Ruster L,McGee R, et al. Interleukin 2 receptor antagonistsfor kidney transplant recipients. Cochrane Database Syst Rev 2010; 1:CD003897.
9. Borsig L, Wolf MJ, Roblek M, et al. Inflammatory chemokines andmetastasis-tracing the accessory. Oncogene 2013. Epub July 15, 2013.
10. Eiro N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg2012; 4: 62.
11. Fox P, Hudson M, Brown C, et al. Markers of systemic inflammationpredict survival in patients with advanced renal cell cancer. Br JCancer 2013; 109: 147.
12. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk ofgraft loss and risk of non-Hodgkin lymphoma with induction agentsin renal transplant recipients. Transplantation 2006; 81: 1227.
13. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and therisk of post-transplant malignancy among cadaveric first kidneytransplant recipients. Am J Transplant 2004; 4: 87.
14. Cherikh WS, Kauffman HM, McBride MA, et al. Association ofthe type of induction immunosuppression with posttransplant lymphoproliferativedisorder, graft survival, and patient survival afterprimary kidney transplantation. Transplantation 2003; 76: 1289.
15. van Leeuwen M, Grulich A,Webster A, et al. Immunosuppression andother risk factors for early and late non-Hodgkin lymphoma afterkidney transplantation. Blood 2009; 114: 630.
16. Webster AC, Pankhurst T, Rinaldi F, et al. Monoclonal and polyclonalantibody therapy for treating acute rejection in kidney transplant recipients:a systematic review of randomized trial data. Transplantation2006; 81: 953.
17. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of posttransplantlymphoproliferative disease in kidney transplant recipients.Br J Surg 2001; 88: 1330.
18. Benkerrou M, Durandy A, Fischer A. Therapy for transplantrelatedlymphoproliferative diseases. Hematol Oncol Clin North Am1993; 7: 467.
19. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomasand lymphoproliferative lesions developing under cyclosporin-steroidtherapy. Lancet 1984; 1: 583.
20. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, et al. Immunesystem: a double-edged sword in cancer. Inflamm Res 2013.Epub July 23, 2013.
21. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387.
22. Hardinger KL. Rabbit antithymocyte globulin induction therapy inadult renal transplantation. Pharmacotherapy 2006; 26: 1771.
23. Midtvedt K, Fauchald P, Lien B, et al. Individualized T cell monitoredadministration of ATG versus OKT3 in steroid-resistant kidney graftrejection. Clin Transplant 2003; 17: 69.
24. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistanceto monoclonal antibody therapy. Semin Oncol 2003; 30: 424.
25. Halloran PF. Immunosuppressive drugs for kidney transplantation.N Engl J Med 2004; 351: 2715.
26. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer riskamong US solid organ transplant recipients. JAMA 2011; 306: 1891.
27. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidneytransplantation in the United States. Am J Transplant 2004; 4: 905.
28. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renaltransplantation in the Nordic countries, 1964-1986. Int J Cancer1995; 60: 183.
29. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viralimmunity. J Exp Med 2012; 209: 1391.
30. Kim KH, Han EM, Lee ES, et al. Epstein-Barr virus infection insarcomatoid renal cell carcinoma tissues. BJU Int 2005; 96: 547.
31. Salehipoor M, Khezri A, Behzad-Behbahani A, et al. Role of viruses inrenal cell carcinoma. Saudi J Kidney Dis Transplant 2012; 23: 53.
32. Comar M, Bonifacio D, Zanconati F, et al. High prevalence of BKpolyomavirus sequences in human papillomavirus-16-positive precancerouscervical lesions. J Med Virol 2011; 83: 1770.
33. Bialasiewicz S, Cho Y, Rockett R, et al. Association of micropapillaryurothelial carcinoma of the bladder and BK viruria in kidney transplantrecipients. Transplant Infect Dis 2013; 15: 283.
34. Wong G, Howard K,Webster A, et al. The health and economic impactof cervical cancer screening and human papillomavirus vaccination inkidney transplant recipients. Transplantation 2009; 87: 1078.
35. Howell M, Tong A, Wong G, et al. Important outcomes for kidneytransplant recipients: a nominal group and qualitative study. Am JKidney Dis 2012; 60: 186.
36. Williams NC, Tong A, Howard K, et al. Knowledge, beliefs and attitudesof kidney transplant recipients regarding their risk of cancer.Nephrology (Carlton) 2012; 17: 300.
37. Zhang X, Zhang MJ. SAS macros for estimation of direct adjustedcumulative incidence curves under proportional subdistributionhazards models. Comp Methods Prog Biomed 2011; 101: 87.